Non familial primary hyperparathyroidism
Conditions
Interventions
Product Name: 18F-Fluormethylcholine
Product Code: not applicable
Pharmaceutical Form: Solution for injection
Sponsors
UMC Utrecht
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients who have signed informed consent - Age = 18 years - Biochemically proven PHP - Indication for surgery - Negative SPECT/CT Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 8 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 2
Exclusion criteria
Exclusion criteria: - Pregnancy - Patients with MEN syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Investigating the added value of 18F-Fluormethylcholine PET/CT for localising the pathological parathyroid in patients with biochemically proven primary hyperparathyroidism;Secondary Objective: To investigate possible factors that influence the outcome of the scan ;Primary end point(s): post-operative ionised calcium serum level ;Timepoint(s) of evaluation of this end point: 1 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Pathology report of the resected parathyroid(s);Timepoint(s) of evaluation of this end point: 1 week post-operative | — |
Countries
Netherlands
Contacts
Public ContactShanta Kalaykhan-Sewradj
UMC Utrecht
Outcome results
None listed